Supplementary Table 1 Cytotoxic effects of CD37 antibodies and controls on CLL samples
and associated clinical and molecular features.
Age/
Sex
Stage
(Binet)
Treat- Karyotype
ment2
IgVH 3
ZAP70 4 CD38 4
A
B
C
D
E
F
G
H
I
J
K8
L
M
N
m / 55
f / 79
f / 76
m / 47
m / 69
m / 78
m / 54
f / 63
m / 74
m / 77
m / 60
m / 67
f / 43
m / 63
B
A
A
A
B
C
A
A
A
A/B
A
A
A
C
u
t
u
u
t
t
u
del13q14
del13q
del13q14
n.d.
del17p 7
n.d.
del13q
del13q het.
n.d.
n.d.
del13q14
del13q
n.d.
del17p
del13q
n.d. 6
n.d.
n.d.
um
n.d.
n.d.
M
M
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n
n.d.
p
p
p
p
n
n
n.d.
p
n.d.
n.d.
n
p
n
n.d.
n
p
p
p
n
n
n.d.
p
n.d.
n
n
p
% cytotoxic effects5 after
treatment with 10 µg/ml
MAB37.1 (MAB37.2);
rituximab, alemtuzumab
6 (7); 1, 5
7 (0); 2, 1
24 (14); 10, n.d.
29 (14); 1, 10
38 (n.d.); 10, 54
42 (4); 17, 27
62 (62); 23, n.d.
64 (11); 10, 21
68 (27); 8, 47
70 (59); 62, 79
71 (50); 6, 34
71 (46); 16, 24
82 (62); 17, 36
84 (57); 29, 76
1
2
3
47
5
6
7
m / 65
m / 65
m / 54
m / 60
f / 61
f / 54
m / 68
n.d.
C
n.d.
A
B
n.d.
C
t
t
t
n.d.
u
t
t
n.d.
M
um
n.d.
n.d.
n.d.
n.d.
n
p
n
n.d.
n
n.d.
p
n
p
p
n.d.
n
n.d.
p
0 (0); 20, n.d.
5 (3); 18, n.d.
5 (29) 9; 20, n.d.
11 (21); 2, n.d.
11 (29); 0, n.d.
18 (0); 4, n.d.
18 (0); 5, n.d.
8
9
10
11
12
f / 48
m / 51
f / 59
f / 44
f / 60
n.d.
C
B
A
C
n.d.
t
t
u
n.d.
n.d.
n.d.
n.d.
M
n.d.
n.d.
p
n
n
p
n.d.
n
n
n
p
20 (27); 0, n.d.
21 (18); 0, n.d.
23 (2); 35, n.d.
23 (11); 11, n.d.
23 (26); 27, n.d.
13
14
m / 73 A
m / 70 B
u
t
M
M
n
n
n
n
27 (10); 2, n.d.
30 (10); 1, n.d.
15
16
17
18
19
20
21
22
23
m / 46
m / 56
m / 61
m / 73
m / 69
m / 79
m / 73
f / 64
m / 69
n.d.
u
u
n.d.
t
u
u
n.d.
u
n.d.
n.d.
del11q
del13q14
normal
n.d.
Trisomy 12,
del 11q
n.d.
del11q
n.d.
normal
trisomy 12
del13q14
normal
del11q; del
13q
n.d.
normal
normal
n.d.
n.d.
n.d. 4
del13q14
del13q14
n.d.
M
n.d.
n.d.
n.d.
um
n.d.
M
n.d.
n.d.
n
n
n
n
p
n
n
n
n
n
n.d.
n.d.
n
p
n
p
n
n
30 (16); 4, n.d.
31 (5); 0, n.d.
41 (32); 24, n.d.
43 (34); 11, n.d.
43 (12); 8, n.d.
63 (37); 0, n.d.
66 (14); 32, n.d.
68 (39); 15, n.d.
75 (68); 16, n.d.
ID
no. 1
A
A
A
A
B/C
A
A
n.d.
n.d.
n.d.
u
n.d.
t
u
t
1
Individual CLL samples were arranged according to ascending mAb 37.1-induced DCD
(samples A to N) or B cell depletion (1 to 23).
2
u (untreated) / t (treated): never treated / with prior treatment (more than three months
ago); n.d.: not determined.
3
um (unmutated) / M (mutated): <2 % / >2 % sequence divergence with the closest
germline gene.
4
p (positive) / n (negative): percentage of cells with higher fluorescence after staining with
specific antibody than with isotype antibody >20 % / < 20 %.
5
For the freshly isolated CLL samples A to N the percentage of non-viable, i.e. annexin Vpositive cells, relative to untreated controls was determined after 24 h of treatment with
the indicated antibodies. In the same manner, antibody-induced B cell depletion after an
equal treatment period is indicated for the whole blood samples no. 1 to 23. In both
groups, samples are arranged according to ascending mAb 37.1 effects.
6
n.d.: not determined.
7
Deletions of chromosomes 17p and 11q, on which the p53 and ATM genes are located,
are printed in bold.
8
Samples K and 4 were isolated CLL lymphocytes and whole blood, respectively, from the
same patient.
9
Results printed in italics and highlighted by yellow shading untypically show higher mAb
37.1 than mAb 37.2 effects.